Developer docs
API playgroundTry for free, no card

Search company profiles

Centrient Pharmaceuticals

Full company profile

uuid0008af1

Namestring
Centrient Pharmaceuticals
Legal namestring
Centrient Pharmaceuticals Netherlands B.V.
Websiteurl
centrient.com
Company typeenum
Private
Founded yearint
1874
Descriptiontext

Centrient Pharmaceuticals is a Netherlands-headquartered B2B pharmaceutical manufacturer specializing in sustainable, enzymatically produced antibiotics, next-generation statins, and anti-fungals. Operating from a network of manufacturing sites and sales offices across the Netherlands, Spain, India, China, Mexico, and Singapore, the company is 100% owned by Bain Capital Private Equity following a 2016 acquisition. Centrient supplies Active Pharmaceutical Ingredients (APIs), key intermediates such as 6-APA and 7-ADCA, and Finished Dosage Forms (FDFs) to generic pharmaceutical companies worldwide, with branded product families including Purimox®, Puricillin®, Purilex®, and Puriclor® across penicillin and cephalosporin antibiotics, and atorvastatin and rosuvastatin statins.

The company's core differentiation rests on its proprietary PureActives® enzymatic platform, introduced in 2012 and protected by over 400 patents in approximately 80 patent families. PureActives® replaces the traditional 13-step chemical synthesis process with an enzymatic process operating at ambient temperatures, delivering a 63% reduction in carbon footprint, avoidance of harmful solvents, batch sizes up to 10x larger than competitors, and APIs of measurably higher purity and stability. The technology underpins regulatory positioning as a founding Board Member of the AMR Industry Alliance (2017), a member of the Pharmaceutical Supply Chain Initiative (2016) and Critical Medicines Alliance (2024), and a recipient of BSI Minimized Risk of AMR certification at two manufacturing sites (Santa Perpètua 2024, Toansa 2025) and five consecutive EcoVadis Gold sustainability ratings.

The business model operates on quote-based enterprise pricing across B2B customers including generic drug manufacturers, FDF producers, and generics marketers. Centrient employs approximately 1,800-2,700 people across 14-22 locations in roughly 14 countries, with backward-integrated supply chains spanning intermediates through FDFs. Revenue streams include one-time sales of APIs and intermediates, FDF out-licensing of regulatory dossiers, and ongoing technology licensing under the patent portfolio. The company's strategic posture is anchored on supply security for foundational medicines, regulatory leadership in antimicrobial resistance (AMR), and ESG-driven differentiation versus Asian API competitors, supported by near-term climate targets validated through EcoVadis (46.2% Scope 1/2 and 27.5% Scope 3 emissions reduction by 2031).

Short descriptiontext

Centrient Pharmaceuticals is a Netherlands-based B2B manufacturer of sustainable enzymatic antibiotics, statins, and anti-fungals, supplying APIs, intermediates, and finished dosage forms to global generic pharmaceutical companies under its proprietary PureActives® platform. The company is 100% owned by Bain Capital Private Equity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersRotterdam, Netherlands
HQ citystring
Rotterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, enzymatic antibiotic production, generic pharmaceutical supply, finished dosage forms, statins manufacturing
Industry3 codes
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Ingredients Manufacturing
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Active Pharmaceutical Ingredients (APIs)
TypeOne Time License
Description

Manufacture and sale of high-quality, sustainable active pharmaceutical ingredients including antibiotics, statins, and anti-fungals using proprietary enzymatic technology.

centrient.com
2Intermediates
TypeOne Time License
Description

Production of pharmaceutical intermediates including 6-APA and 7-ADCA for beta-lactam antibiotics, providing backward integration and supply chain security.

centrient.com
3Finished Dosage Forms (FDFs)
TypeOne Time License
Description

Supply of finished dosage forms including tablets, capsules, and oral suspensions, with state-of-the-art dossiers available for out-licensing.

centrient.com
4Technology Licensing
TypeLicensing Royalties
Description

Customers enjoy freedom to operate using enzymatically produced APIs, with technologies protected by over 400 patents.

centrient.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Technology or R&D, Personnel, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PureActives®
Description

Proprietary enzymatic platform technology that replaces traditional 13-step production process for antibiotics with more efficient, natural processes requiring less energy and water, avoiding harmful solvents

centrient.com
Core offering1 text field

Centrient Pharmaceuticals manufactures and supplies Active Pharmaceutical Ingredients (APIs), intermediates (6-APA, 7-ADCA), and Finished Dosage Forms (FDFs) for antibiotics (penicillins, cephalosporins), next-generation statins (atorvastatin, rosuvastatin), and anti-fungals (nystatin, caspofungin). The company sells these B2B to generic drug manufacturers worldwide, producing them via its proprietary PureActives® enzymatic technology platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 63% reduction in carbon footprint compared to traditional chemical process
+4 more records
Product overview1 text field

Centrient Pharmaceuticals is a global business-to-business supplier of sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. The company operates as a single unified pharmaceutical product portfolio consisting of Active Pharmaceutical Ingredients (APIs), intermediates, and Finished Dosage Forms (FDFs). The core proprietary technology is PureActives®, an enzymatic platform introduced in 2012 that produces antibiotics (Penicillins including Amoxicillin and Ampicillin; Cephalosporins including Cephalexin, Cefadroxil, Cefradine, Cefaclor) and statins (Atorvastatin, Rosuvastatin) more sustainably than traditional chemical processes. The antibiotics portfolio also includes key intermediates 6-APA and 7-ADCA, plus isoxazole penicillins (Cloxacillin, Dicloxacillin, Flucloxacillin) and Penicillin G variants. Anti-fungals include Caspofungin and Nystatin variants. FDFs include Amoxicillin standalone and combination products with Clavulanic acid, plus Atorvastatin and Rosuvastatin tablets. All products are marketed as B2B offerings to generic pharmaceutical companies.

Product and service1 record
1Purimox (Amoxicillin trihydrate)
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Critical Medicines Alliance (CMA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Joined in 2024 to reinforce commitment to strengthening pharmaceutical supply chain resilience in Europe. CMA was set up by European Union agency HERA to identify priorities for action and strengthen supply of critical medicines in the EU.

centrient.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-10-01
Description

Partner for STEM programme workshops on antibiotic manufacturing discharge and advanced technologies for removing antibiotic residues from pharmaceutical waste.

3AMR Industry Alliance
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-05-01
Description

Centrient is a Board Member of the AMR Industry Alliance since its inception in May 2017. The Alliance brings together pharmaceutical companies, generics, diagnostics, and biotech companies to collectively deliver on commitments to curb antimicrobial resistance. Centrient actively participates in developing PNEC targets and manufacturing frameworks.

centrient.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-11-01
Description

Member since November 2016; PSCI comprises 24 pharmaceutical and healthcare companies promoting responsible supply chain management. Centrient plays a leading role in establishing industry-wide guidelines for responsible antibiotic production.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Member of Cefic, a not-for-profit organization representing chemical companies across Europe. Centrient participates in APIC (Active Pharmaceutical Ingredients Committee) for regulatory affairs and quality management.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ACS Dobfar is an Italian-headquartered manufacturer of antibiotics APIs, intermediates (6-APA, 7-ADCA), and finished dosage forms — directly comparable to Centrient's antibiotics-focused portfolio and backward-integrated supply chain model. Both companies serve global generic pharmaceutical customers with beta-lactam and cephalosporin APIs.

TypeBroad incumbent
Description

Aurobindo Pharma is one of the world's largest Indian generic pharmaceutical manufacturers with substantial in-house API manufacturing across antibiotics, statins, and antifungals — overlapping directly with Centrient's product portfolio while operating at significantly larger scale across finished dosage forms.

TypeDirect peer
Description

Zhejiang Huahai is a major Chinese manufacturer of generic APIs including cardiovascular drugs (statins) and finished dosage forms. The company competes directly with Centrient in atorvastatin and rosuvastatin APIs, and represents a key competitor in the global generic API supply chain.

4Sun Pharmaceutical Industries
TypeBroad incumbent
Description

Sun Pharma is India's largest generic pharmaceutical company with significant API manufacturing capabilities and a global generics portfolio including antibiotics and statins. Comparable to Centrient in product categories served, though operates at much larger scale with direct retail and consumer health exposure.

5Sandoz
TypeBroad incumbent
Description

Sandoz is the recently spun-off generics division of Novartis and the world's largest generic pharmaceutical company by revenue. It is a major buyer of APIs from companies like Centrient and represents both a key customer and an indirect benchmark for what backward-integrated generics manufacturing looks like at scale.

TypeBroad incumbent
Description

Viatris (formed from Mylan and Upjohn) is a global pharmaceutical company with a broad generics portfolio and significant API supply relationships. As one of the world's largest generic drug marketers with deep antibiotics exposure, it represents both a customer segment and a comparable player in generic supply chain management.

TypeBroad incumbent
Description

Teva is the world's largest generic pharmaceutical manufacturer with extensive API manufacturing operations and a leading position in antibiotics and statins. While much larger and more diversified, Teva's API arm provides a benchmark for vertically integrated generic pharmaceutical manufacturing at scale.

TypeBroad incumbent
Description

Dr. Reddy's is a major Indian-headquartered generic pharmaceutical company with strong API manufacturing capabilities and a global generics portfolio. Comparable to Centrient in serving global generic pharmaceutical buyers, with direct overlap in antibiotics and statins APIs.

TypeBroad incumbent
Description

Apotex is the largest Canadian-owned generic pharmaceutical manufacturer with vertically integrated API manufacturing operations and global supply capabilities. The company is a direct customer-competitor in generic APIs and competes in similar supply channels.

TypeDirect peer
Description

CSPC is a large Chinese pharmaceutical company with significant API manufacturing operations and an emerging global generics presence. It competes with Centrient in supplying generic APIs to global pharmaceutical companies, particularly in cardiovascular and anti-infective categories.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance13 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Centrient Pharmaceuticals

Pharmaceutical Ingredients Manufacturingcentrient.com

Centrient Pharmaceuticals is a Netherlands-based B2B manufacturer of sustainable enzymatic antibiotics, statins, and anti-fungals, supplying APIs, intermediates, and finished dosage forms to global generic pharmaceutical companies under its proprietary PureActives® platform. The company is 100% owned by Bain Capital Private Equity.

What Centrient Pharmaceuticals does

Centrient Pharmaceuticals is a Netherlands-headquartered B2B pharmaceutical manufacturer specializing in sustainable, enzymatically produced antibiotics, next-generation statins, and anti-fungals. Operating from a network of manufacturing sites and sales offices across the Netherlands, Spain, India, China, Mexico, and Singapore, the company is 100% owned by Bain Capital Private Equity following a 2016 acquisition. Centrient supplies Active Pharmaceutical Ingredients (APIs), key intermediates such as 6-APA and 7-ADCA, and Finished Dosage Forms (FDFs) to generic pharmaceutical companies worldwide, with branded product families including Purimox®, Puricillin®, Purilex®, and Puriclor® across penicillin and cephalosporin antibiotics, and atorvastatin and rosuvastatin statins.

The company's core differentiation rests on its proprietary PureActives® enzymatic platform, introduced in 2012 and protected by over 400 patents in approximately 80 patent families. PureActives® replaces the traditional 13-step chemical synthesis process with an enzymatic process operating at ambient temperatures, delivering a 63% reduction in carbon footprint, avoidance of harmful solvents, batch sizes up to 10x larger than competitors, and APIs of measurably higher purity and stability. The technology underpins regulatory positioning as a founding Board Member of the AMR Industry Alliance (2017), a member of the Pharmaceutical Supply Chain Initiative (2016) and Critical Medicines Alliance (2024), and a recipient of BSI Minimized Risk of AMR certification at two manufacturing sites (Santa Perpètua 2024, Toansa 2025) and five consecutive EcoVadis Gold sustainability ratings.

The business model operates on quote-based enterprise pricing across B2B customers including generic drug manufacturers, FDF producers, and generics marketers. Centrient employs approximately 1,800-2,700 people across 14-22 locations in roughly 14 countries, with backward-integrated supply chains spanning intermediates through FDFs. Revenue streams include one-time sales of APIs and intermediates, FDF out-licensing of regulatory dossiers, and ongoing technology licensing under the patent portfolio. The company's strategic posture is anchored on supply security for foundational medicines, regulatory leadership in antimicrobial resistance (AMR), and ESG-driven differentiation versus Asian API competitors, supported by near-term climate targets validated through EcoVadis (46.2% Scope 1/2 and 27.5% Scope 3 emissions reduction by 2031).

Centrient Pharmaceuticals firmographics

Firmographics
Name
Centrient Pharmaceuticals
Legal name
Centrient Pharmaceuticals Netherlands B.V.
Website
https://centrient.com
Company type
Private
Founded year
1874
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Centrient Pharmaceuticals is a Netherlands-based B2B manufacturer of sustainable enzymatic antibiotics, statins, and anti-fungals, supplying APIs, intermediates, and finished dosage forms to global generic pharmaceutical companies under its proprietary PureActives® platform. The company is 100% owned by Bain Capital Private Equity.
Ownership category
akta.pro rank

Centrient Pharmaceuticals industry classification

Industry
Product category
Pharmaceutical Ingredients Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)

Keywords

  • Active pharmaceutical ingredients
  • Enzymatic antibiotic production
  • Generic pharmaceutical supply
  • Finished dosage forms
  • Statins manufacturing

Where Centrient Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Rotterdam
HQ country
Netherlands
HQ region
Europe

Offices8 records

Markets served

Centrient Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

  1. Active Pharmaceutical Ingredients (APIs): Manufacture and sale of high-quality, sustainable active pharmaceutical ingredients including antibiotics, statins, and anti-fungals using proprietary enzymatic technology.
  2. Intermediates: Production of pharmaceutical intermediates including 6-APA and 7-ADCA for beta-lactam antibiotics, providing backward integration and supply chain security.
  3. Finished Dosage Forms (FDFs): Supply of finished dosage forms including tablets, capsules, and oral suspensions, with state-of-the-art dossiers available for out-licensing.
  4. Technology Licensing: Customers enjoy freedom to operate using enzymatically produced APIs, with technologies protected by over 400 patents.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Centrient Pharmaceuticals product offering

Product offering

Core offering

Centrient Pharmaceuticals manufactures and supplies Active Pharmaceutical Ingredients (APIs), intermediates (6-APA, 7-ADCA), and Finished Dosage Forms (FDFs) for antibiotics (penicillins, cephalosporins), next-generation statins (atorvastatin, rosuvastatin), and anti-fungals (nystatin, caspofungin). The company sells these B2B to generic drug manufacturers worldwide, producing them via its proprietary PureActives® enzymatic technology platform.

Product overview

Centrient Pharmaceuticals is a global business-to-business supplier of sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. The company operates as a single unified pharmaceutical product portfolio consisting of Active Pharmaceutical Ingredients (APIs), intermediates, and Finished Dosage Forms (FDFs). The core proprietary technology is PureActives®, an enzymatic platform introduced in 2012 that produces antibiotics (Penicillins including Amoxicillin and Ampicillin; Cephalosporins including Cephalexin, Cefadroxil, Cefradine, Cefaclor) and statins (Atorvastatin, Rosuvastatin) more sustainably than traditional chemical processes. The antibiotics portfolio also includes key intermediates 6-APA and 7-ADCA, plus isoxazole penicillins (Cloxacillin, Dicloxacillin, Flucloxacillin) and Penicillin G variants. Anti-fungals include Caspofungin and Nystatin variants. FDFs include Amoxicillin standalone and combination products with Clavulanic acid, plus Atorvastatin and Rosuvastatin tablets. All products are marketed as B2B offerings to generic pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

  • PureActives®: Proprietary enzymatic platform technology that replaces traditional 13-step production process for antibiotics with more efficient, natural processes requiring less energy and water, avoiding harmful solvents

Products and services

  • Purimox (Amoxicillin trihydrate)

Quantifiable outcome

  • 63% reduction in carbon footprint compared to traditional chemical process
  • +4 more outcomes

Companies that use Centrient Pharmaceuticals

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Centrient Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Centrient Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Critical Medicines Alliance (CMA)coreStrategic or Co-development Partner · 1 January 2024Joined in 2024 to reinforce commitment to strengthening pharmaceutical supply chain resilience in Europe. CMA was set up by European Union agency HERA to identify priorities for action and strengthen supply of critical medicines in the EU.
  • Indian Institute of TechnologyminorStrategic or Co-development Partner · 1 October 2019Partner for STEM programme workshops on antibiotic manufacturing discharge and advanced technologies for removing antibiotic residues from pharmaceutical waste.
  • AMR Industry AlliancecoreStrategic or Co-development Partner · 1 May 2017Centrient is a Board Member of the AMR Industry Alliance since its inception in May 2017. The Alliance brings together pharmaceutical companies, generics, diagnostics, and biotech companies to collectively deliver on commitments to curb antimicrobial resistance. Centrient actively participates in developing PNEC targets and manufacturing frameworks.
  • Pharmaceutical Supply Chain Initiative (PSCI)coreStrategic or Co-development Partner · 1 November 2016Member since November 2016; PSCI comprises 24 pharmaceutical and healthcare companies promoting responsible supply chain management. Centrient plays a leading role in establishing industry-wide guidelines for responsible antibiotic production.
  • Cefic (European Chemical Industry Council)minorStrategic or Co-development PartnerMember of Cefic, a not-for-profit organization representing chemical companies across Europe. Centrient participates in APIC (Active Pharmaceutical Ingredients Committee) for regulatory affairs and quality management.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Centrient Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • ACS Dobfar: ACS Dobfar is an Italian-headquartered manufacturer of antibiotics APIs, intermediates (6-APA, 7-ADCA), and finished dosage forms — directly comparable to Centrient's antibiotics-focused portfolio and backward-integrated supply chain model. Both companies serve global generic pharmaceutical customers with beta-lactam and cephalosporin APIs.
  • Zhejiang Huahai Pharmaceutical: Zhejiang Huahai is a major Chinese manufacturer of generic APIs including cardiovascular drugs (statins) and finished dosage forms. The company competes directly with Centrient in atorvastatin and rosuvastatin APIs, and represents a key competitor in the global generic API supply chain.
  • CSPC Pharmaceutical Group: CSPC is a large Chinese pharmaceutical company with significant API manufacturing operations and an emerging global generics presence. It competes with Centrient in supplying generic APIs to global pharmaceutical companies, particularly in cardiovascular and anti-infective categories.

Broad incumbents

  • Aurobindo Pharma: Aurobindo Pharma is one of the world's largest Indian generic pharmaceutical manufacturers with substantial in-house API manufacturing across antibiotics, statins, and antifungals — overlapping directly with Centrient's product portfolio while operating at significantly larger scale across finished dosage forms.
  • Sun Pharmaceutical Industries: Sun Pharma is India's largest generic pharmaceutical company with significant API manufacturing capabilities and a global generics portfolio including antibiotics and statins. Comparable to Centrient in product categories served, though operates at much larger scale with direct retail and consumer health exposure.
  • Sandoz: Sandoz is the recently spun-off generics division of Novartis and the world's largest generic pharmaceutical company by revenue. It is a major buyer of APIs from companies like Centrient and represents both a key customer and an indirect benchmark for what backward-integrated generics manufacturing looks like at scale.
  • Viatris: Viatris (formed from Mylan and Upjohn) is a global pharmaceutical company with a broad generics portfolio and significant API supply relationships. As one of the world's largest generic drug marketers with deep antibiotics exposure, it represents both a customer segment and a comparable player in generic supply chain management.
  • Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive API manufacturing operations and a leading position in antibiotics and statins. While much larger and more diversified, Teva's API arm provides a benchmark for vertically integrated generic pharmaceutical manufacturing at scale.
  • Dr. Reddy's Laboratories: Dr. Reddy's is a major Indian-headquartered generic pharmaceutical company with strong API manufacturing capabilities and a global generics portfolio. Comparable to Centrient in serving global generic pharmaceutical buyers, with direct overlap in antibiotics and statins APIs.
  • Apotex: Apotex is the largest Canadian-owned generic pharmaceutical manufacturer with vertically integrated API manufacturing operations and global supply capabilities. The company is a direct customer-competitor in generic APIs and competes in similar supply channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Centrient Pharmaceuticals social profiles

Digital presence

Centrient Pharmaceuticals compliance and trust

Trust signal

Compliance13 records

Centrient Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Centrient Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Centrient Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Centrient Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Centrient Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centrient Pharmaceuticals

What does Centrient Pharmaceuticals do?

Centrient Pharmaceuticals manufactures and supplies Active Pharmaceutical Ingredients (APIs), intermediates (6-APA, 7-ADCA), and Finished Dosage Forms (FDFs) for antibiotics (penicillins, cephalosporins), next-generation statins (atorvastatin, rosuvastatin), and anti-fungals (nystatin, caspofungin). The company sells these B2B to generic drug manufacturers worldwide, producing them via its proprietary PureActives® enzymatic technology platform.

Is Centrient Pharmaceuticals a public or private company?

Centrient Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.

When was Centrient Pharmaceuticals founded?

Centrient Pharmaceuticals was founded in 1874. It employs 501 to 1,000 people.

Where is Centrient Pharmaceuticals based?

Centrient Pharmaceuticals is headquartered in Rotterdam, Netherlands, in the Europe region.

How does Centrient Pharmaceuticals make money?

Four revenue lines are on record. Active Pharmaceutical Ingredients (APIs) is the primary driver. The others are intermediates, finished Dosage Forms (FDFs) and technology Licensing.

Who are Centrient Pharmaceuticals's main competitors?

Direct peers on record are ACS Dobfar, Zhejiang Huahai Pharmaceutical and CSPC Pharmaceutical Group. Broad incumbents are Aurobindo Pharma, Sun Pharmaceutical Industries, Sandoz, Viatris, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories and Apotex.

Does Centrient Pharmaceuticals have an API?

No public API is recorded for Centrient Pharmaceuticals.

What industry is Centrient Pharmaceuticals in?

Centrient Pharmaceuticals's product category is Pharmaceutical Ingredients Manufacturing. Its primary akta.pro industry code is HLAIABAG, Generic APIs & Intermediates (Active Ingredients), with a secondary code of HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HrtodayCentrient Pharmaceuticals Appoints Genevieve Machin as Chief People and Transformation OfficerCentrient Pharmaceuticals announced the appointment of Genevieve Machin as its new Chief People and Transformation Officer, a role that will see her lead the company's global people strategy, HR governance, and enterprise-wide transformation programs. Machin joins from the NATO Support and Procurement Agency where she served as Chief Human Resources Officer, bringing over 25 years of HR and transformation experience from organizations including Gates Corporation, CHAMP Cargosystems, and PolyOne. The appointment is framed as strategically important for the pharmaceutical ingredients company as it seeks to strengthen its position in sustainable antibiotics, statins, and anti-fungals amid growing focus on healthcare resilience and antimicrobial resistance.BloombergBain Is Exploring €1 Billion Sale of Centrient PharmaBain Capital is exploring a sale of Centrient Pharmaceuticals, an antibodies manufacturer, potentially valued at €1 billion ($1.1 billion). The private equity firm is working with Citigroup and Jefferies on a possible divestment of the Netherlands-based company.PharmiWeb.comCentrient Pharmaceuticals joins Almirall’s growing innovation hub in BarcelonaAlmirall and Centrient Pharmaceuticals agreed to open a dedicated innovation lab at Almirall's R&D center in Sant Feliu de Llobregat, with operations starting in the first quarter of 2024. The lab will focus on Centrient's biotechnology expertise, including strain conservation, enzyme development, and fermentation. The partnership aims to diversify Centrient's product portfolio and accelerate its evolution into an innovation partner.YahooCentrient Pharmaceuticals joins Almirall’s growing innovation hub in BarcelonaAlmirall and Centrient Pharmaceuticals agreed to open a dedicated innovation lab at Almirall's R&D center in Sant Feliu de Llobregat, Barcelona, with operations starting in Q1 2024. The lab will focus on Centrient's biotechnology expertise, including strain conservation and enzyme processing, supporting Centrient's diversification into an innovation partner.Business Wire BlogCentrient Pharmaceuticals joins Almirall’s growing innovation hub in BarcelonaAlmirall and Centrient Pharmaceuticals agreed to open a dedicated innovation lab at Almirall's R&D center in Barcelona, starting operations in Q1 2024. The lab will focus on Centrient's biotechnology expertise, including strain conservation and enzyme processing. The partnership supports Centrient's strategic roadmap leading into 2030.Business Wire BlogCentrient Pharmaceuticals joins Almirall’s growing innovation hub in BarcelonaAlmirall and Centrient Pharmaceuticals agreed to open a dedicated innovation lab at Almirall's R&D center in Sant Feliu de Llobregat, Barcelona, with operations starting in the first quarter of 2024. The lab will focus on Centrient's biotechnology expertise, including strain conservation, enzyme development, and fermentation. The partnership aims to diversify Centrient's product portfolio and accelerate its evolution into an innovation partner.PR NewswireNEW CERTIFICATION AIMS TO MITIGATE ANTIMICROBIAL RESISTANCE RISK IN ANTIBIOTIC MANUFACTURINGBSI launched a new global Minimized Risk of Antimicrobial Resistance (AMR) certification on World Environment Day (June 5, 2023) in London to promote responsible antibiotic manufacturing and minimize antibiotic waste emissions into the environment. The certification offers independent third-party verification that waste streams containing antibiotic active pharmaceutical ingredients are properly controlled during manufacturing. Several major pharmaceutical companies including Pfizer, Roche, Sandoz, Teva, Viatris, Centrient, and Haupt Pharma Latina participated in a pilot program and are already seeking certification, with the program becoming available globally to all antibiotic manufacturers.PR NewswireGinkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API SpaceGinkgo Bioworks and Centrient Pharmaceuticals expanded their partnership to broaden Centrient's sustainable API portfolio. Ginkgo delivered an enzyme that improved efficiency, reducing the environmental footprint of amoxicillin and cephalexin production. Centrient plans ongoing strain projects to further cut carbon emissions and waste.GlobeNewswireCentrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibioticsCentrient Pharmaceuticals announced full compliance with AMR Industry Alliance PNEC discharge targets for its oral antibiotics supply chain, covering its own and supplier sites. The company states this is the first in the industry to publicly declare such compliance, aiming to minimize antimicrobial resistance risk.GlobeNewswireCentrient Pharmaceuticals boosting statins API manufacturing capacityCentrient Pharmaceuticals started production at its new statins API unit in Toansa, India, doubling its Atorvastatin and Rosuvastatin capacity. The expansion meets growing demand for its sustainably produced statins, which cut carbon footprint by 32% versus traditional manufacturers.